ReviewInternational journal of molecular medicine2025
m6A modification of non‑coding RNA: Mechanisms, functions and potential values in human diseases (Review).
Review in International journal of molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Effects of Isorhapontigenin on Cell Viability, Colony-Forming Efficiency, and Ferroptosis via Methyltransferase-Like 14-Mediated mMolecular carcinogenesis · 2026Article
- CircRHBDD1(4,5) drives malignant progression of oral squamous cell carcinoma by enhancing DKK1 mRNA stability through facilitating mOncogene · 2026Article
- RNA Chemical Modifications in Mammalian Skeletal Muscle Development, Homeostasis, and Disease: Regulatory Mechanisms and Chemical Biology Perspectives.Molecules (Basel, Switzerland) · 2026Review
- Article
- Metabolic remodeling by circular RNAs in gastric tumorigenesis: From mechanisms to biomarker discovery (Review).International journal of oncology · 2026Review
- The Role of NMedComm · 2026Review
- The m6A-circRNA axis: a therapeutic prospect for gastric cancer.Cell biology and toxicology · 2026Review
- mbioRxiv : the preprint server for biology · 2026Article
- Morinda officinalis polysaccharide improves osteoporosis by enhancing m⁶A-modified SOCS5 mRNA stability via regulating the hsa_circ_0001165/IGF2BP2 axis.Molecular genetics and genomics : MGG · 2026Article
- Integrated Bioinformatics Analysis Reveals the Impact of SHEV ORF3-Related LncRNA Network on Bile Secretion Pathway (ko 04976) in HepG2 Cells.Veterinary sciences · 2026Article
- Emerging functions of m6A-modified circRNAs and their targeting strategies in lung cancer.Frontiers in cell and developmental biology · 2026Review
- Destabilization of hsa_circ_0015508 by YTHDF2 Enhances miR-496-Mediated FOXN3 Suppression to Drive Nasopharyngeal Carcinoma Progression.Oncology research · 2026Article
- Research hotspots and frontiers in the tumor microenvironment of gastric cancer: a bibliometric review from 2005 to 2024.Translational cancer research · 2025Article
- The role of microRNAs in primary Sjögren's disease: deciphering regulatory networks and assessing current therapeutic perspectives.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
N6‑methyladenosine (m6A) RNA modification represents a pivotal and novel post‑transcriptional modification in eukaryotic RNAs. Initially identified in messenger RNAs (mRNAs), m6A modification on these transcripts regulates a spectrum of essential cellular processes, including mRNA splicing, subcellular localization, stability and translation. Recent studies have highlighted the involvement of m6A methylation in both biological and pathological processes, particularly in cancer. Non‑coding RNAs (ncRNAs), a diverse class of RNA molecules that do not encode proteins, encompass microRNAs, long ncRNAs and circular RNAs. Notably, m6A has been recognized as a reversible epigenetic modification within ncRNAs, a discovery that has garnered considerable attention. This modification not only influences the stability of ncRNAs but also endows them with the novel capacity for peptide translation. The differential and specific expression pattern in diseases give these m6A‑modified ncRNAs potential as biomarkers for molecular diagnostics and targeted therapy, and using ncRNA‑encoded peptides as a target for immunotherapy has also been attempted. This review synthesizes the current understanding of m6A modifications in ncRNAs, explores the effects of m6A on ncRNA function and presents the latest insights into the role of ncRNA m6A modifications in disease progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.